Profiting from innovations: the role of new game strategies in the case of Lipitor of the US pharmaceutical industry

Author: Afuah, Afuah, Afuah, Allen, Aschhoff, Barney, Bekkers, Belderbos, Bowman, Brandenburger, Buaron, Burt, Burt, Chesbrough, Cohen, Dierickx, Dyer, Finney, Freeman, Funk, Garud, Grosse, Hagedoorn, Hagedoorn, Henderson, Keil, Leafstedt, Leonard-Barton, Levit, Lieberman, Lieberman, Mitchell, Nelson, Nielsen, Porter, Rothaemel, Schrader, Schumpeter, Si, Teece, Teece, Tripsas, von Hippel, von Hippel, von Hippel, Walter, Williamson, Williamson, Zaheer
Publisher: Wiley

ABOUT BOOK

In exploring why innovators often do not profit from their innovations, researchers concentrate on innovators versus imitators and the extent to which owners of complementary assets capture profits from innovations. The literature provides scant attention to factors that sap profits from innovations. This paper argues that an innovator's positioning vis-à-vis customers, suppliers, complementors, and other co-opetitors plays a critical role in the innovator's profitability. The article explores how an innovator can use new game strategies to better positioning, thus capturing rents from innovations and enabling further innovations in the future. The study examines the case of Lipitor, one of the world's best-selling drug, to illustrate how positioning can play in a firm's ability to profit from its innovations.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/79168/1/j.1467-9310.2010.00597.x.pd

Powered by: